Foley Hoag LLP represented Ginkgo Bioworks on the agreement. Ginkgo Bioworks (NYSE: DNA) announced a collaboration with Pfizer (NYSE: PFE) focused on the discovery of RNA-based drug...
You must be a Standard 1 Year member to access this content.
Foley Hoag represented Ginkgo Bioworks on the deal. Ginkgo Bioworks (NYSE: DNA) (“Ginkgo”), the leading platform for cell programming and biosecurity, announced its acquisition of StrideBio’s adeno-associated...
You must be a Standard 1 Year member to access this content.
Foley Hoag LLP represented Vergent Bioscience, Inc. on the deal. Vergent Bioscience, Inc. (“Vergent”), a clinical-stage biotechnology company developing tumor-targeted imaging agents, announced a $21.5 million Series...
You must be a Standard 1 Year member to access this content.
Foley Hoag LLP represented Ginkgo Bioworks, Inc. on the deal. Ginkgo Bioworks, Inc. (NYSE: DNA), the leading horizontal platform for cell programming, closed a collaboration agreement with...
You must be a Standard 1 Year member to access this content.
Foley Hoag LLP represented Satellite Bio on the deal. Satellite Bio, a regenerative medicine company raised $110 million in Seed and Series A funding. The recent Series A...
You must be a Standard 1 Year member to access this content.
